Skip to main content

David A. Lowe, PhD

Deputy Chief Scientific Officer at AC Immune SA

Location: Lausanne Switzerland

David A. Lowe, PhD, leads the Parkinson’s Disease Therapeutics and Imaging programs at AC Immune. Previously, Dr. Lowe was the chief scientific officer (CSO) at PsychoGenics Inc.; CSO at Memory Pharmaceuticals (acquired by Roche); executive vice president and CSO at Fidelity Biosciences Group in Boston; president, CEO and director of Envivo Pharmaceuticals (now Forum Pharmaceuticals); vice president and therapeutic area head at Roche Bioscience in Palo Alto; vice president and global therapeutic area head at Bayer AG.; and head of CNS Biology and deputy head of CNS Research at Sandoz Ltd (now Novartis).

Dr. Lowe has more than 35 years of experience in pharmaceutical drug discovery and product development, with an established track record of generating diverse clinical candidates. He received his PhD in neurobiology from the University of Leeds, UK and has published over 60 papers in peer reviewed journals.   

Associated Grants

  • New Imaging Agents for Parkinson's Disease and Related Disorders


  • Development of PET Tracers for Synucleinopathies


  • Development of Novel, Small Molecule Compounds as PET Tracers for Synucleinopathies


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.